Astrana Health Inc (ASTH)vsDaVita HealthCare Partners Inc (DVA)
ASTH
Astrana Health Inc
$37.98
-0.13%
HEALTHCARE · Cap: $1.89B
DVA
DaVita HealthCare Partners Inc
$181.55
+0.12%
HEALTHCARE · Cap: $11.74B
Smart Verdict
WallStSmart Research — data-driven comparison
DaVita HealthCare Partners Inc generates 264% more annual revenue ($14.01B vs $3.84B). DVA leads profitability with a 6.0% profit margin vs 1.1%. DVA trades at a lower P/E of 15.6x. DVA earns a higher WallStSmart Score of 70/100 (B).
ASTH
Buy56
out of 100
Grade: C
DVA
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASTH.
Margin of Safety
-13.0%
Fair Value
$127.66
Current Price
$181.55
$53.89 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 48.5% year-over-year
Earnings expanding 110.5% YoY
Reasonable price relative to book value
Growing faster than its price suggests
Every $100 of equity generates 81 in profit
Earnings expanding 55.8% YoY
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
Smaller company, higher risk/reward
ROE of 3.8% — below average capital efficiency
1.1% margin — thin
Operating margin of 3.5%
6.0% margin — thin
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ASTH
The strongest argument for ASTH centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 48.5% demonstrates continued momentum.
Bull Case : DVA
The strongest argument for DVA centers on PEG Ratio, Return on Equity, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.
Bear Case : ASTH
The primary concerns for ASTH are Market Cap, Return on Equity, Profit Margin. A P/E of 46.4x leaves little room for execution misses. Thin 1.1% margins leave little buffer for downturns.
Bear Case : DVA
The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.
Key Dynamics to Monitor
ASTH profiles as a hypergrowth stock while DVA is a value play — different risk/reward profiles.
ASTH carries more volatility with a beta of 0.91 — expect wider price swings.
ASTH is growing revenue faster at 48.5% — sustainability is the question.
DVA generates stronger free cash flow (320M), providing more financial flexibility.
Bottom Line
DVA scores higher overall (70/100 vs 56/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Astrana Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.
DaVita HealthCare Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?